Génome Canada

Génome Canada
Génome Québec

Génome Québec

October 17, 2007 13:40 ET

Genome Canada and Genome Quebec Applaud the Publication of the Second Generation of the Haplotype Map of the Human Genome (HapMap) by Nature Magazine

MONTREAL, QUEBEC--(Marketwire - Oct. 17, 2007) - The International HapMap Consortium is publishing the results of phase II of the "haplotype map" of the human genome (HapMap) in the October 18, 2007 issue of Nature. Genome Canada and Genome Quebec, partners in HapMap, are pleased to salute the success of this major international project. A number of Canadian scientists have been part of the success of this international project since its beginnings, including Dr. Thomas J. Hudson while scientific director of the Genome Quebec / McGill University Innovation Centre and Bartha Maria Knoppers, professor in the Universite de Montreal's faculty of law.

The HapMap project has made large-scale genomic association studies possible. This publication exemplifies the important role of the HapMap project in our understanding of human genetic variations and their connection with disease.

The second generation of the "haplotype map" of the human genome contains three times more genetic markers than the first version unveiled in 2005. In the prestigious magazine Nature, the Consortium explains that the higher resolution of this second version offers a greater ability to detect the genetic variations involved in certain illnesses; studies the structure of human genetic variation and makes it possible to learn how certain environmental factors influence the human genome. This research could result in new methods for the prevention, diagnosis and treatment of disease.

"The research results apply to all individuals and represent an invaluable contribution for scientists the world over," said Martin Godbout, President and CEO of Genome Canada. "The HapMap Consortium is truly an example of international collaboration involving players from the industrial, academic and government sectors in the study of the minute fraction of human genetic material that varies among individuals and that could explain the differences observed in disease susceptibility, drug response and reactions to different environmental factors."

"HapMap is a real scientific revolution that phenomenally enhances our capacity to analyse genetic variations. The success of HapMap illustrates our desire to promote the expertise of our scientists on the international stage," said Paul L'Archeveque, President and CEO of Genome Quebec. "We are proud to pay homage to the two Quebec scientists who have played a leadership role since the beginning of the project. This project is fully consistent with the strategic objectives for innovation established by Quebec's Ministere du Developpement economique, de l'Innovation et de l'Exportation."

The International HapMap Consortium is a partnership of scientists and financing organizations from Canada, China, Japan, Nigeria, the U.K. and the United States, the objective of which is to develop a public resource that will allow scientists to establish links between genetic variations and the risk of contracting certain diseases.

About Genome Canada:

Genome Canada is a private, non-profit corporation, and the primary funding and information resource relating to genomics and proteomics research in Canada. Its principal goal is to position Canada among the world leaders in genomics and proteomics research. Its mandate is to develop and implement a national strategy in genomics and proteomics research for the benefit of all Canadians in key selected area such as agriculture, environment, fisheries, forestry, animal and human health, and new technology. For this purpose, it has received $700 million in funding from the Canadian government and co-funding from other partners over seven years, allowing it to invest a total of $1.5 billion in 115 innovative research projects and technology platforms. To learn more about Genome Canada, please visit our Web site at www.genomecanada.ca

About Genome Quebec:

The mission of Genome Quebec is to mobilize academic and industrial sectors with regard to genomics and proteomics research. This private non-profit organization invests and manages funds totalling over $380 million from both the private and public sectors. Genome Quebec currently manages projects in six major sectors: human health, bioinformatics, ethics, the environment, and forestry and agricultural sciences. To find out more about Genome Quebec and genomics, visit its Web site at www.genomequebec.com.

Contact Information

  • Genome Canada
    Claudine Renauld
    Vice President, Communications and Public Affairs
    613-751-4460 ext. 129
    or
    Genome Québec
    Louise Thibault
    Project Manager, Communications
    514-398-0668 ext. 232